Gyre Therapeutics, Inc. GYRE EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Gyre Therapeutics, Inc.’s reported figures.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s EBITDA?
- Gyre Therapeutics, Inc. (GYRE) reported EBITDA of -$8.68M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s EBITDA changed year-over-year?
- Gyre Therapeutics, Inc.'s EBITDA decreased by 409.2% year-over-year, from $2.81M to -$8.68M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s EBITDA?
- Over 3 years (2021 to 2025), Gyre Therapeutics, Inc.'s EBITDA has grown at a -45.8% compound annual growth rate (CAGR), from -$87.6M to $13.97M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.